Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11550
Title: Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy.
Authors: Knights, Ashley J;Fucikova, Jitka;Pasam, Anupama;Koernig, Sandra;Cebon, Jonathan S
Affiliation: Ludwig Institute for Cancer Research Melbourne, Austin Branch, Austin Hospital, 145-163 Studley Road, Heidelberg, VIC, 3084, Australia. Ashley.Knights@ludwig.edu.au
Issue Date: 26-Aug-2012
Citation: Cancer Immunology, Immunotherapy : Cii 2012; 62(2): 321-35
Abstract: Inhibitor of apoptosis proteins (IAPs) are critical in regulating apoptosis resistance in cancer. Antagonists of IAPs, such as LCL161, are in clinical development and show promise as anti-cancer agents for solid and hematological cancers, with preliminary data suggesting they may act as immunomodulators. IAP antagonists hypersensitize tumor cells to TNF-α-mediated apoptosis, an effect that may work in synergy with that of cancer vaccines. This study aimed to further investigate the immunomodulatory properties of LCL161 on human immune subsets. T lymphocytes treated with LCL161 demonstrated significantly enhanced cytokine secretion upon activation, with little effect on CD4 and CD8 T-cell survival or proliferation. LCL161 treatment of peripheral blood mononuclear cells significantly enhanced priming of naïve T cells with synthetic peptides in vitro. Myeloid dendritic cells underwent phenotypic maturation upon IAP antagonism and demonstrated a reduced capacity to cross-present a tumor antigen-based vaccine. These effects are potentially mediated through an observed activation of the canonical and non-canonical NF-κB pathways, following IAP antagonism with a resulting upregulation of anti-apoptotic molecules. In conclusion, this study demonstrated the immunomodulatory properties of antagonists at physiologically relevant concentrations and indicates their combination with immunotherapy requires further investigation.
Internal ID Number: 22923192
URI: http://ahro.austin.org.au/austinjspui/handle/1/11550
DOI: 10.1007/s00262-012-1342-1
URL: http://www.ncbi.nlm.nih.gov/pubmed/22923192
Type: Journal Article
Subjects: Antigens, Neoplasm.immunology.pharmacology
Antineoplastic Agents.pharmacology
Apoptosis.drug effects
Cancer Vaccines.pharmacology
Cells, Cultured
Combined Modality Therapy
Cytokines.secretion
Dendritic Cells.drug effects.immunology
Humans
Immunotherapy
Inhibitor of Apoptosis Proteins.antagonists & inhibitors
Leukocytes, Mononuclear.drug effects.immunology
NF-kappa B.metabolism
Peptides.pharmacology
T-Lymphocytes.drug effects.immunology
Thiazoles.pharmacology
Up-Regulation.drug effects
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
22923192.pdf64.91 kBAdobe PDFView/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.